REJUVENATION TREATMENT OF AGE-RELATED WHITE MATTER LOSS CROSS REFERENCE TO RELATED APPLICATION

The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to r...

Full description

Saved in:
Bibliographic Details
Main Authors DA COSTA BARBEDO VIEIRA, Ricardo, GOLDMAN, Steven
Format Patent
LanguageEnglish
French
Published 27.04.2023
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof. La présente invention concerne l'atténuation des effets indésirables de la perte d'oligodendrocytes, de la perte d'astrocytes ou de la perte de substance blanche, y compris la perte d'oligodendrocytes liée à l'âge, la perte d'astrocytes liée à l'âge ou la perte de substance blanche liée à l'âge, dans le cerveau d'un sujet. La présente application concerne également la régénération d'une cellule progénitrice gliale ou d'une de ses progénitures, ou l'amélioration du potentiel de développement d'une cellule progénitrice gliale ou d'une de ses progénitures.
Bibliography:Application Number: WO2022US78356